



IFW

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)			Docket No.	
Applicant(s): Dekkers et al.			143565-1	
Application No. 10/798,183	Filing Date 03/11/2004	Examiner W.K. Cheung	Customer No. 23413	Group Art Unit 1713
Invention: <b>BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF</b>				
<div style="text-align: center;"></div>				
<p>I hereby certify that this <u>IDS Form 1449 (1 p); Transmittal (2 p); IDS Statement (1 p); (2) Cited References</u> (Identify type of correspondence)</p> <p>is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>August 5, 2005</u> (Date)</p> <div style="text-align: right;"><p><u>Candace H. Buswell</u> (Typed or Printed Name of Person Mailing Correspondence)</p><p> (Signature of Person Mailing Correspondence)</p></div>				
<p style="text-align: center;">Note: Each paper must have its own certificate of mailing.</p> <div style="border: 1px solid black; padding: 10px; min-height: 200px;"><p>Transmittal of IDS (2 pgs) IDS Form 1449 (1 pg) IDS Statement (1 pg) Cited References (2) Certificate of Mailing Postcard Receipt</p></div>				

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. 143565-1	
In Re Application Of:    Dekkers et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/798,183	March 11, 2004	W.K. Cheung	23413	1713	5302	
Title: <b>BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF</b>						
<div style="text-align: center;"> <p>Address to:</p> <p>Commissioner for Patents</p> <p>P.O. Box 1450</p> <p>Alexandria, VA 22313-1450</p> </div> <div style="text-align: center; margin-top: 10px;"> <p><b>37 CFR 1.97(b)</b></p> </div> <p>1.   <input checked="" type="checkbox"/>   The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <p><b>37 CFR 1.97(c)</b></p> </div> <p>2.   <input type="checkbox"/>   The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px; margin-top: 10px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-top: 10px;"><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

143565-1

In Re Application of: Dekkers et al.

AUG 08 2005

Application No.

10/798,183

Filing Date

March 11, 2004

Examiner

W.K. Cheung

Customer No.

23413

Group Art Unit

1713

Confirmation No.

5302

Title: **BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☒ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

August 5, 2005

(Date)

Signature of Person Mailing Correspondence

Candace H. Buswell

Typed or Printed Name of Person Mailing Certificate


\*This certificate may only be used if paying by deposit account.

*Karen A. LeCuyer*  
Signature

Dated: August 5, 2005

Karen A. LeCuyer, Ph.D.  
Registration No. 51,928  
Cantor Colburn LLP  
55 Griffin Road South  
Bloomfield, CT 06002  
Telephone: (860) 286-2929  
Facsimile: (860) 286-0115

CC:



Docket No. 143565-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dekkers et al.

Serial No.: 10/798,183

Filing Date: March 11, 2004

For: BIOCIDAL COMPOSITIONS AND METHODS  
OF MAKING THEREOF

)  
) Group Art Unit: 1713  
)  
) Examiner: W.K. Cheung  
)  
)  
)  
)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made by the applicant, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: Karen A. LeCuyer  
Karen A. LeCuyer, Ph.D.  
Registration No. 51,928

Date: August 5, 2005  
Customer No.: 23413  
Telephone: (860) 286-2929

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				Docket Number (Optional) <b>143565-1</b>		Application Number <b>10/798,183</b>		
				Applicant(s) <b>Dekkers et al.</b>		Group Art Unit <b>1713</b>		
				Filing Date <b>March 11, 2004</b>				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		6,365,220 B1	04/02/2002	Burrell et al.	427	2.1	01/07/2000	
		6,093,422	07/25/2000	Denkewicz, Jr. et al.	424	618	06/16/1998	
		4,775,585	10/04/1998	Hagiwara et al.	428	323	01/29/1987	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 01/46900 A1	06/28/2001	PCT				
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		International Search Report; PCT/US2005/008582; date mailed 6/14/2005;						
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								